In Sydney, a carefully designed clinical trial answered a reasonable question with an honest negative: testosterone therapy, despite its biological promise, did not help postmenopausal women with early heart failure breathe easier, move further, or live better. The hypothesis was sound, the methodology rigorous, and the hormone levels achieved as intended — yet the outcomes that matter most to patients remained unmoved. This is not a story of failure, but of science doing the slow, unglamorous work of drawing boundaries around what is true.